Palvella Therapeutics (NASDAQ:PVLA) Trading Up 5.9% – Here’s Why

Palvella Therapeutics, Inc. (NASDAQ:PVLA)’s share price was up 5.9% during mid-day trading on Monday . The company traded as high as $90.69 and last traded at $90.69. Approximately 14,713 shares traded hands during trading, a decline of 94% from the average daily volume of 252,856 shares. The stock had previously closed at $85.66.

Wall Street Analyst Weigh In

A number of research firms have recently commented on PVLA. HC Wainwright set a $200.00 price objective on Palvella Therapeutics and gave the stock a “buy” rating in a research note on Monday, December 15th. UBS Group reiterated a “buy” rating and set a $143.00 price target on shares of Palvella Therapeutics in a report on Monday, December 15th. Raymond James Financial reissued a “strong-buy” rating and issued a $193.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. Canaccord Genuity Group boosted their target price on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Finally, Mizuho began coverage on shares of Palvella Therapeutics in a research note on Wednesday, January 7th. They set an “outperform” rating and a $205.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $158.69.

Palvella Therapeutics Stock Up 1.0%

The business has a 50-day moving average price of $91.60 and a 200-day moving average price of $77.61. The firm has a market capitalization of $1.02 billion, a P/E ratio of -32.90 and a beta of -0.16.

Insider Activity

In other news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. grew its stake in shares of Palvella Therapeutics by 11.6% in the 4th quarter. Invesco Ltd. now owns 54,273 shares of the company’s stock valued at $5,681,000 after purchasing an additional 5,663 shares during the period. XTX Topco Ltd acquired a new stake in Palvella Therapeutics in the 4th quarter valued at $429,000. Virtus Investment Advisers LLC bought a new stake in Palvella Therapeutics in the fourth quarter valued at $282,000. Superstring Capital Management LP acquired a new position in Palvella Therapeutics during the fourth quarter worth $2,666,000. Finally, Suvretta Capital Management LLC raised its stake in Palvella Therapeutics by 8.5% during the fourth quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock worth $93,408,000 after acquiring an additional 70,000 shares in the last quarter. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.